Zacks Investment Research

Recent Articles

FedEx to Buy Cargex to Expand Its Presence in Latin America

By

FedEx's (FDX) decision to buy the Colombia-based freight forwarding company is likely to strengthen the company's foothold in the Latin American market

Will Apple’s New Devices Boost Its Flagging iPhone Sales?

By

AAPL is rumored lto aunch its iPhone 11 series next month. The series is expected to boost flagging iPhone sales backed by strong feature upgrades and enhancements.

Is Toyota Motor a Suitable Stock for Value Investors?

By

Let's see if TM stock is a good choice for value-oriented investors right now. Toyota Motor stock has multiple, favorable valuation metrics.

Are You Looking for a High-Growth Dividend Stock? Caterpillar Stock Could Be a Great Choice

By

Caterpillar (CAT) stock may have what it takes to attract income-oriented investors. Over the last five years, CAT has increased its dividend four times on a year-over-year basis.

Best Buy Stock Declines Despite Q2 Earnings Beat

By

Though Best Buy's (BBY) earnings and sales improved year-over-year, the top line missed the Zacks Consensus Estimate.

Lululemon’s EPS Expected to Climb: What LULU Stock Owners Should Know Ahead of Next Week’s Release

By

LULU possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Owners and prospective buyers of LULU stock should examine these factors.

Facebook, Apple, Amazon, or Netflix: Time to Buy a Few FAANG Stocks Again?

By

Should investors consider buying some FAANG stocks, such as Netflix stock, Facebook, Apple or Amazon?

ULTA Reporting After the Bell Today: Will ULTA Stock Remain a Retail Jewel?

By

ULTA stock has had some strong, positive catalysts, including ULTA's ability to meet the needs of its younger customers.

Nike Stock Is Outpacing the Market: What You Should Know

By

Nike stock closed yesterday at $83.48, gaining 1.77% from the previous trading session. NKE stock is also outpacing the market in early trading today.

Amgen to Buy Celgene’s Otezla for $13.4B: Is the Deal Good for Amgen Stock?

By

Amgen's purchase of Celgenes blockbuster psoriasis drug, Otezla is likely to strengthen its position in the immunology space and boost Amgen stock.

Load More